Valuation: Intellipharmaceutics International Inc.

Market Cap 1.41M 1.2M 1.12M 1.03M 1.94M 135M 1.98M 13.33M 5.2M 67.57M 5.28M 5.17M 224M P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 3.65M 3.12M 2.92M 2.68M 5.03M 349M 5.13M 34.59M 13.48M 175M 13.7M 13.4M 580M EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 2007-03-31
Corporate Officer/Principal - 2014-01-31
Director TitleAgeSince
Director/Board Member - 2004-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-2.81%+1.98%+76.96%+127.73% 1,141B
-2.21%+2.50%+50.38%+55.01% 659B
-1.56%+5.25%+26.98%+74.39% 470B
+1.20%+1.72%+42.89%+45.78% 366B
-0.61%+1.72%+25.21%+41.34% 302B
+0.32%+3.30%+2.60%+13.42% 254B
-1.95%+4.22%+46.75%+65.66% 239B
-1.10%-1.12%-14.91%-52.66% 207B
-2.82%+5.57%+21.58%+89.04% 183B
Average -0.48%+3.69%+30.94%+51.08% 382.1B
Weighted average by Cap. -0.06%+4.31%+44.42%+70.86%

Financials

2021 2022
Net sales - 65.73K 56.26K 52.57K 48.2K 90.57K 6.29M 92.37K 623K 243K 3.16M 247K 241K 10.45M
Net income -5.15M -4.4M -4.12M -3.77M -7.09M -492M -7.23M -48.77M -19.01M -247M -19.32M -18.9M -818M -2.89M -2.48M -2.31M -2.12M -3.99M -277M -4.06M -27.42M -10.68M -139M -10.86M -10.62M -460M
Net Debt 1.15M 980K 916K 840K 1.58M 110M 1.61M 10.86M 4.23M 55.03M 4.3M 4.21M 182M 2.24M 1.92M 1.79M 1.64M 3.09M 215M 3.15M 21.26M 8.28M 108M 8.42M 8.23M 356M
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock